Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01673009 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
A Phase 2 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT01673009 is a Phase 2 study that has completed, run by Indiana University. The registered enrollment target is 36 participants.
The verdict
NCT01673009, a Phase 2 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
THe primary objective is to estimate the response rate at 6 months to Gleevec® in patients with plexiform neurofibromas
Interventions
- DRUG Gleevec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2006-05 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01673009
The ClinicalTrials.gov registry entry for NCT01673009 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gleevec is the first listed.
NCT01673009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01673009 about?
NCT01673009 is a clinical study titled "Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas". THe primary objective is to estimate the response rate at 6 months to Gleevec® in patients with plexiform neurofibromas
What is the current status of trial NCT01673009?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2006-05. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01673009?
The interventions under investigation include: Gleevec (DRUG).
Who is sponsoring clinical trial NCT01673009?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.